Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spanish study tracks CLL Patients' Well-Being on standard oral therapies

NCT ID NCT06125795

Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches how people with chronic lymphocytic leukemia (CLL) feel and function while taking standard oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. No new drugs are given—the goal is simply to learn which treatment schedules (fixed-time or continuous) may better support quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

146 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants diagnosed with chronic lymphocytic leukemia (CLL) treated with fixed-time duration (FTD) or continuous oral regimens who attend to a regular follow up visit at a Spanish participating hospital will be eligible to participate in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have documented chronic lymphocytic leukemia (CLL) according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. * Under oral treatment for CLL, either first-line or relapsed/refractory (R/R) therapy. * Treatment for CLL started 9 months (+/- 4 weeks) before inclusion for first-line therapy or 21 months (+/- 4 weeks) before inclusion for R/R, under authorized conditions. * In the opinion of the investigator, cognitive ability to understand and answer the questionnaires specified in the study protocol. * Able to comply with the study protocol in the investigator's judgment. Exclusion Criteria: * Currently receiving any chemotherapy or chemoimmunotherapy. * Transformation of CLL to aggressive non-Hodgkin's lymphoma (NHL) (Richter's transformation or pro-lymphocytic leukaemia). * Currently participating in interventional research (not including non-interventional study, post-marketing observational study, or registry participation). * Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia neoplasm Patient Preference

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia

Contacts and locations

Locations

  • HUA - Txagorritxu /ID# 258263

    Vitoria-Gasteiz, Alava, 01009, Spain

  • Hospital Clinico Universitario Virgen de la Arrixaca /ID# 262173

    El Palmar, Murcia, 30120, Spain

  • Hospital Comarcal de Laredo /ID# 258262

    Laredo, Cantabria, 39770, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 258273

    Madrid, 28007, Spain

  • Hospital General Universitario Morales Meseguer /ID# 258284

    Murcia, 30008, Spain

  • Hospital Jerez De La Frontera /ID# 258282

    Jerez de la Frontera, Cadiz, 11407, Spain

  • Hospital Lucus Augusti /ID# 271542

    Lugo, 27004, Spain

  • Hospital Meixoeiro (CHUVI) /ID# 258286

    Vigo, Pontevedra, 36213, Spain

  • Hospital Universitari Mútua Terrassa /ID# 258267

    Terrassa, Barcelona, 08221, Spain

  • Hospital Universitario 12 de Octubre /ID# 258271

    Madrid, 28041, Spain

  • Hospital Universitario Central de Asturias /ID# 271508

    Oviedo, Principality of Asturias, 33011, Spain

  • Hospital Universitario Dr. Negrin /ID# 258285

    Las Palmas de Gran Canaria, Las Palmas, 35019, Spain

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 258269

    Madrid, 28040, Spain

  • Hospital Universitario La Paz /ID# 258270

    Madrid, 28046, Spain

  • Hospital Universitario Marques de Valdecilla /ID# 258261

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Reina Sofia /ID# 271507

    Córdoba, 14004, Spain

  • Hospital Universitario Virgen Macarena /ID# 258279

    Seville, 41009, Spain

  • Hospital Universitario Virgen de las Nieves /ID# 258280

    Granada, 18014, Spain

  • Hospital Universitario de Fuenlabrada /ID# 258275

    Fuenlabrada, Madrid, 28942, Spain

  • Hospital Universitario de Galdakao /ID# 258264

    Galdakao, Vizcaya, 48960, Spain

  • Hospital Universitario de La Princesa /ID# 271506

    Madrid, 28006, Spain

  • Hospital Universitario de León /ID# 271526

    León, Leon, 24080, Spain

  • Hospital de Cabuenes /ID# 263307

    Gijón, Principality of Asturias, 33394, Spain

  • Hospital de Sant Joan Despi Moises Broggi /ID# 262284

    Barcelona, 08906, Spain

  • Sant Joan de Deu de Manresa /ID# 258266

    Manresa, Barcelona, 08423, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.